<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "JATS-journalpublishing1.dtd">
<article article-type="letter" dtd-version="1.1" specific-use="sps-1.9" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="nlm-ta">Rev Saude Publica</journal-id>
			<journal-id journal-id-type="publisher-id">rsp</journal-id>
			<journal-title-group>
				<journal-title>Revista de Saúde Pública</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Rev. Saúde Pública</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0034-8910</issn>
			<issn pub-type="epub">1518-8787</issn>
			<publisher>
				<publisher-name>Faculdade de Saúde Pública da Universidade de São Paulo</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="other">00801</article-id>
			<article-id pub-id-type="doi">10.11606/s1518-8787.2022056004923</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Letter to the Editor</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>An incomplete step in the right direction: Peru’s National Institute of Health establishes cost-effectiveness threshold</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-8879-6354</contrib-id>
					<name>
						<surname>Saldarriaga</surname>
						<given-names>Enrique M.</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>I</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>I</label>
				<institution content-type="orgname">University of Washington</institution>
				<institution content-type="orgdiv1">CHOICE</institution>
				<addr-line>
					<named-content content-type="city">Seattle</named-content>
					<named-content content-type="state">WA</named-content>
				</addr-line>
				<country country="US">United States</country>
				<institution content-type="original">University of Washington. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute. Seattle, WA, United States</institution>
			</aff>
			<author-notes>
				<corresp id="c01"> Correspondence: Enrique M. Saldarriaga 1959 NE Pacific St. Health Science Building, H-375 Seattle, Washington, USA E-mail: <email>emsb@uw.edu</email>
				</corresp>
				<fn fn-type="conflict">
					<p>Conflict of Interest: The author declares no conflict of interest.</p>
				</fn>
			</author-notes>
			<pub-date date-type="pub" publication-format="electronic">
				<day>06</day>
				<month>01</month>
				<year>2023</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic">
				<year>2022</year>
			</pub-date>
			<volume>56</volume>
			<elocation-id>106</elocation-id>
			<history>
				<date date-type="received">
					<day>5</day>
					<month>07</month>
					<year>2022</year>
				</date>
				<date date-type="accepted">
					<day>19</day>
					<month>08</month>
					<year>2022</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/" xml:lang="en">
					<license-p> This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </license-p>
				</license>
			</permissions>
			<counts>
				<fig-count count="0"/>
				<table-count count="0"/>
				<equation-count count="0"/>
				<ref-count count="7"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<disp-quote>
			<p>Seattle, June 20, 2022</p>
			<p>Revista de Saúde Pública</p>
		</disp-quote>
		<p>Dear Editor,</p>
		<p>The Peruvian National Institute of Health (INS – <italic>Instituto Nacional de Salud del Perú</italic>) established for the first time in the country a cost-effectiveness (CE) threshold for the analysis of interventions, health technologies and pharmaceutical products<sup><xref ref-type="bibr" rid="B1">1</xref></sup>. This threshold is an essential element for investment decision-making as it signals which interventions are most likely to create benefits above their implementation and maintenance costs. The INS determined that an intervention will be cost-effective if its cost per unit of health gained is between 2.2 and 4.4 times the value of a tax unit (UIT – <italic>Unidad Impositiva Tributaria</italic>) valued at 4,600PEN in 2022<sup><xref ref-type="bibr" rid="B2">2</xref></sup>; in dollars, between 2,663 and 5,326USD. In the following paragraphs I present why I believe this is a step in the right direction albeit incomplete.</p>
		<p>This decision is appropriate for three reasons. First, it provides an objective, quantifiable, and standard element of analysis for health investments decision-making. In addition, it facilitates the comparison of economic feasibility between interventions that would not be comparable otherwise. Second, by establishing the range based on an independent measure (the UIT) that is updated annually based on macroeconomic criteria, it increases the probability of being sustained over time and of being adopted by the scientific community. Third, the range established is in line with the growing literature that strongly criticizes the use of GDP-based thresholds as being insufficiently responsive to the opportunity cost of public investment in settings (i.e., countries, regions) with limited access to resources and therefore with a higher need for prioritization of resources<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup>. In a recent study, Kazibwe et al.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> analyzed 197 health economic evaluations and found that all those from Latin America used CE thresholds based on the country’s GDP per capita. The stipulation of the INS is thus a pioneering step in Latin America, where the literature on methodologies for health technology assessment is scarce and shows a preference for thresholds based on GDP<sup><xref ref-type="bibr" rid="B6">6</xref></sup>.</p>
		<p>Despite these attributes, the range has some limitations. First, although there is debate about the best ways to use and calculate the CE threshold, in practice there is agreement that it should represent the opportunity cost of financing an intervention from the healthcare sector or societal perspectives<sup><xref ref-type="bibr" rid="B7">7</xref></sup>. Thus, it is not clear what is the logic behind linking the CE threshold to the UIT. It is not evident what is the relationship of this tax unit with Peru’s health sector budget, the technical or financial capacity of the health provider, or the preferences of the population; which would have been expected of an instrument that seeks to serve as an investment guide. The UIT is an instrument used in taxation and therefore correlated with economic activity in general, but not necessarily with the spending capacity of the health sector. Second, the INS’s statement does not describe which health unit was considered during the establishment of the threshold. This is relevant because the health consequences in economic evaluations can be expressed in different health units – usually years of life gained, quality of life-adjusted health years (QALYs) or years lost due to disability (DALYs) – that represent different types of public health gains and therefore willingness to invest. While the INS directive would not be expected to establish which health unit researchers and health technology assessment officers should use, because that is their prerogative, it could provide further instructions for an appropriate usage. The immediate consequence of the lack of clarity in this regard is that interventions using only life-years to demonstrate effectiveness will look much more cost-effective than interventions using comprehensive measures of health production such as QALYs and DALYs.</p>
		<p>In conclusion, the establishment of a range of CE by the INS is a very important tool for the system of technological evaluations in Peru. However, its adoption in the long-term by the scientific community will depend on being able to explain the correlation between the UIT and the willingness to pay or spending capacity of the health system for improvements in health outcomes, as well as having more information on what health outcome was considered for its determination and usage.</p>
	</body>
	<back>
		<ref-list>
			<title>REFERENCES</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. Ministerio de Salud (PE). Resolución Ministerial N° 159-2022/MINSA, de 4 de marzo de 2022. Establecer el umbral de costo - efectividad de las evaluaciones de tecnologías sanitarias realizadas por la Dirección General de Medicamentos, Insumos y Drogas y por el Instituto Nacional de Salud. Lima (PE); 2022.</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Ministerio de Salud (PE)</collab>
					</person-group>
					<source>Resolución Ministerial N° 159-2022/MINSA, de 4 de marzo de 2022. Establecer el umbral de costo - efectividad de las evaluaciones de tecnologías sanitarias realizadas por la Dirección General de Medicamentos, Insumos y Drogas y por el Instituto Nacional de Salud</source>
					<publisher-loc>Lima (PE)</publisher-loc>
					<year>2022</year>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. Ministerio de Economia y Finanzas (PE). Decreto Supremo Nº 398-2021EF, de 30 de diciembre de 2021. Valor de la Unidad Impositiva Tributaria durante el año 2022. (Lima (PE); 2021.</mixed-citation>
				<element-citation publication-type="report">
					<person-group person-group-type="author">
						<collab>Ministerio de Economia y Finanzas (PE)</collab>
					</person-group>
					<source>Decreto Supremo Nº 398-2021EF, de 30 de diciembre de 2021. Valor de la Unidad Impositiva Tributaria durante el año 2022</source>
					<publisher-loc>Lima (PE)</publisher-loc>
					<year>2021</year>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016;19(8):929-35. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jval.2016.02.017">https://doi.org/10.1016/j.jval.2016.02.017</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Woods</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Revill</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Sculpher</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Claxton</surname>
							<given-names>K</given-names>
						</name>
					</person-group>
					<article-title>Country-level cost-effectiveness thresholds: initial estimates and the need for further research</article-title>
					<source>Value Health</source>
					<year>2016</year>
					<volume>19</volume>
					<issue>8</issue>
					<fpage>929</fpage>
					<lpage>935</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jval.2016.02.017">https://doi.org/10.1016/j.jval.2016.02.017</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Revill P, Walker S, Madan J, Ciaranello A, Mwase T, Gibb DM, Claxton K, et al. Using cost-effectiveness thresholds to determine value for money in low-and middle-income country healthcare systems: are current international norms fit for purpose? York (UK): Centre for Health Economics, University of York; 2014. (Working Paper. CHE Research paper).</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>Revill</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Walker</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Madan</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ciaranello</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Mwase</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Gibb</surname>
							<given-names>DM</given-names>
						</name>
						<name>
							<surname>Claxton</surname>
							<given-names>K</given-names>
						</name>
						<etal>et al</etal>
					</person-group>
					<source>Using cost-effectiveness thresholds to determine value for money in low-and middle-income country healthcare systems: are current international norms fit for purpose?</source>
					<publisher-loc>York (UK)</publisher-loc>
					<publisher-name>Centre for Health Economics, University of York</publisher-name>
					<year>2014</year>
					<comment>Working Paper. CHE Research paper</comment>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Kazibwe J, Gheorge A, Wilson D, Ruiz F, Chalkidou K, Chi YL. The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review. Value Health. 2022;25(3):385-9. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jval.2021.08.014">https://doi.org/10.1016/j.jval.2021.08.014</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kazibwe</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Gheorge</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Wilson</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Ruiz</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Chalkidou</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Chi</surname>
							<given-names>YL</given-names>
						</name>
					</person-group>
					<article-title>The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review</article-title>
					<source>Value Health</source>
					<year>2022</year>
					<volume>25</volume>
					<issue>3</issue>
					<fpage>385</fpage>
					<lpage>389</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jval.2021.08.014">https://doi.org/10.1016/j.jval.2021.08.014</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. Augustovski F, Garay OU, Pichon-Riviere A, Rubinstein A, Caporale JE. Economic evaluation guidelines in Latin America: a current snapshot. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):525-37. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/erp.10.56">https://doi.org/10.1586/erp.10.56</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Augustovski</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Garay</surname>
							<given-names>OU</given-names>
						</name>
						<name>
							<surname>Pichon-Riviere</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Rubinstein</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Caporale</surname>
							<given-names>JE</given-names>
						</name>
					</person-group>
					<article-title>Economic evaluation guidelines in Latin America: a current snapshot</article-title>
					<source>Expert Rev Pharmacoecon Outcomes Res</source>
					<year>2010</year>
					<volume>10</volume>
					<issue>5</issue>
					<fpage>525</fpage>
					<lpage>537</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/erp.10.56">https://doi.org/10.1586/erp.10.56</ext-link>
					</comment>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Thokala P, Ochalek J, Leech AA, Tong T. Cost-effectiveness thresholds: the past, the present and the future. Pharmacoeconomics. 2018;36(5):509-22. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40273-017-0606-1">https://doi.org/10.1007/s40273-017-0606-1</ext-link>
				</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Thokala</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Ochalek</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Leech</surname>
							<given-names>AA</given-names>
						</name>
						<name>
							<surname>Tong</surname>
							<given-names>T</given-names>
						</name>
					</person-group>
					<article-title>Cost-effectiveness thresholds: the past, the present and the future</article-title>
					<source>Pharmacoeconomics</source>
					<year>2018</year>
					<volume>36</volume>
					<issue>5</issue>
					<fpage>509</fpage>
					<lpage>522</lpage>
					<comment>
						<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40273-017-0606-1">https://doi.org/10.1007/s40273-017-0606-1</ext-link>
					</comment>
				</element-citation>
			</ref>
		</ref-list>
	</back>
	<sub-article article-type="translation" id="TRes" xml:lang="es">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Carta al Editor</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Un paso incompleto en la dirección correcta: el Instituto Nacional de Salud del Perú establece el rango de costo-efectividad</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-8879-6354</contrib-id>
					<name>
						<surname>Saldarriaga</surname>
						<given-names>Enrique M.</given-names>
					</name>
					<xref ref-type="aff" rid="aff1003"><sup>I</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1003">
				<label>I</label>
				<country country="US">United States</country>
				<institution content-type="original"> University of Washington. The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute. Seattle, WA, United States</institution>
			</aff>
			<author-notes>
				<corresp id="c01003"> Correspondencia: Enrique M. Saldarriaga 1959 NE Pacific St. Health Science Building, H-375 Seattle, Washington, USA E-mail: emsb@uw.edu </corresp>
				<fn fn-type="conflict">
					<p>Conflicto de Intereses: El autor declara no haber conflicto de intereses.</p>
				</fn>
			</author-notes>
		</front-stub>
		<body>
			<disp-quote>
				<p>Seattle, 20 de junio de 2022</p>
				<p>Revista de Saúde Pública</p>
			</disp-quote>
			<p>Estimado Editor,</p>
			<p>El Instituto Nacional de Salud del Perú (INS) estableció por primera vez en el país un umbral de costo-efectividad (CE) para el análisis de intervenciones y tecnologías de la salud y productos farmacéuticos<sup><xref ref-type="bibr" rid="B1">1</xref></sup>. Dicho umbral es un elemento esencial para la toma de decisiones de inversión pues indica qué intervenciones tienen mayor posibilidad de crear beneficios por encima del costo de su implementación y mantenimiento. El INS estableció que una intervención será costo-efectiva si su costo por unidad de salud ganada es entre 2.2 y 4.4 veces el valor de una unidad impositiva tributaria (UIT) valorizada en 4,600PEN en 2022<sup><xref ref-type="bibr" rid="B2">2</xref></sup> - equivalente a entre 2,663 y 5,326USD. A continuación, expongo por qué considero que este es un paso en la dirección correcta pero incompleto.</p>
			<p>Esta decisión es acertada por tres razones. Primero, es un elemento de análisis objetivo, cuantificable y estándar para la toma de decisiones en inversiones de salud. Adicionalmente, facilita la comparación de factibilidad económica entre intervenciones que de otra forma no serían comparables. Segundo, al establecer el rango en función de una medida (la UIT) independiente y que se actualiza anualmente en función a criterios macroeconómicos, incrementa la probabilidad de ser sostenida en el tiempo y de ser adoptada por la comunidad científica. Tercero, el rango establecido está en concordancia con la creciente literatura que critica fuertemente el uso de rangos basados en el PBI por ser poco sensibles al costo de oportunidad de inversión pública en lugares (países, regiones) con acceso limitado a recursos y que por tanto tienen una necesidad elevada de priorización de recursos<sup><xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref></sup>. En un estudio reciente, Kazibwe et al.<sup><xref ref-type="bibr" rid="B5">5</xref></sup> analizaron 197 evaluaciones económicas en salud y encontraron que todas aquellas provenientes de Latino América utilizaron umbrales de CE basados en el producto bruto interno (PBI) per cápita del país. La estipulación del INS es entonces también un paso pionero en Latino América, donde la literatura sobre metodologías para la evaluación de tecnologías sanitarias es escasa y muestra una preferencia por umbrales basados en PBI<sup><xref ref-type="bibr" rid="B6">6</xref></sup>.</p>
			<p>Sin mengua de estos atributos, el establecimiento de este rango tiene algunas deficiencias. Primero, aun cuando existe debate respecto a las mejores formas de uso y cálculo del umbral de CE, en la práctica hay conceso de que debe representar el costo de oportunidad para el proveedor de salud o la sociedad de financiar una intervención<sup><xref ref-type="bibr" rid="B7">7</xref></sup>. Siendo así, no es claro cuál es la lógica detrás de atar el umbral de CE a la UIT, puesto que no es evidente la relación con el presupuesto de salud del Perú, la capacidad técnica o financiera del proveedor de salud, o las preferencias de la población, como se esperaría de un instrumento que busca fungir de guía de inversiones. La UIT es un instrumento usado en tributación y por lo tanto correlacionado con la actividad económica en general, pero no necesariamente con la capacidad de gasto del sector salud. En segundo lugar, la Norma no establece parámetros para el uso del rango de CE. En particular, qué unidad de salud se consideró durante el establecimiento del umbral. Esto es relevante porque las evaluaciones económicas se pueden expresar en diversas unidades de salud – usualmente años de vida ganados, años de salud ajustados por calidad de vida (AVAC) o perdidos por discapacidad (AVAD) – que representan distintos tipos de ganancia en salud pública y por consiguiente disposición a invertir. Si bien no se esperaría que la Norma del Ministerio de Salud del Perú (MINSA) establezca qué unidad de salud utilizar, pues eso es discreción de los investigadores, sí podría establecer parámetros para su uso. La consecuencia inmediata de la falta de claridad en este sentido es que intervenciones que utilicen únicamente años de vida para demostrar efectividad van a parecer mucho más costo-efectivas que intervenciones que utilizan medidas comprehensivas de producción de salud como AVAC y AVAD.</p>
			<p>En conclusión, el establecimiento de un rango de CE por parte del MINSA es una herramienta muy importante para el sistema de evaluaciones tecnológicas en el Perú. No obstante, su adopción en la comunidad científica y su uso en el largo plazo dependerá de ser posible explicar la correlación entre la UIT y la disposición a pagar o capacidad de gasto del sistema de salud por mejoras en los resultados de salud, así como de tener mayor información sobre qué resultado de salud se tuvo en cuenta para la determinación del umbral.</p>
		</body>
	</sub-article>
</article>